Aura Biosciences Inc AURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AURA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $7.08
- Day Range
- $6.96–7.28
- 52-Week Range
- $5.99–13.50
- Bid/Ask
- $2.89 / $7.22
- Market Cap
- $357.42 Mil
- Volume/Avg
- 116,066 / 186,923
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 89
- Website
- https://www.aurabiosciences.com
Comparables
Valuation
|
Metric
|
AURA
|
CGEM
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.58 | 2.39 | 4.73 |
Price/Sales | — | — | 255.51 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AURA
|
CGEM
|
CLDX
|
|---|---|---|---|
Quick Ratio | 18.30 | 16.60 | 13.69 |
Current Ratio | 18.76 | 17.07 | 13.87 |
Interest Coverage | — | — | — |
Quick Ratio
AURA
CGEM
CLDX
Profitability
|
Metric
|
AURA
|
CGEM
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −32.93% | −24.60% | −30.49% |
Return on Equity (Normalized) | −37.86% | −25.95% | −33.19% |
Return on Invested Capital (Normalized) | −37.41% | −29.67% | −32.85% |
Return on Assets
AURA
CGEM
CLDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cksfbckm | Lyyb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ckgbgpnvc | Qhjchw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cgtxjsb | Yjdfv | $97.8 Bil | |
MRNA
| Moderna Inc | Qhmczbf | Pkjj | $41.3 Bil | |
ARGX
| argenx SE ADR | Rghlzytz | Pghl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Plvcbssp | Fybs | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ysdrzpt | Kknmg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dqfhnwmz | Cskjf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zjswvxmmp | Jzkgkm | $12.5 Bil | |
INCY
| Incyte Corp | Ndljglrp | Mnqvtx | $11.6 Bil |